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ABSTRACT
Percutaneous coronary intervention with drug-eluting bal-
loons has emerged as an adjunctive strategy in the setting 
of Interventional Cardiology. When compared to drug-eluting 
stents, drug-eluting balloons offer advantages such as im-
mediate and homogeneous drug release in the arterial wall, 
absence of polymers that can induce chronic inflammatory 
reactions, and the potential for using dual antiplatelet therapy 
for a shorter period of time. Furthermore, in some situations, 
additional stenting is not desirable, which turns this modality 
into an interesting option. We report the case of a patient 
with acute coronary syndrome in whom this intervention 
was chosen to treat an ostial left anterior descending artery 
in-stent restenosis.
DESCRIPTORS: Coronary restenosis. Percutaneous coronary 
intervention. Angioplasty, balloon. Paclitaxel.
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RESUMO
Eficácia do Balão Farmacológico  
no Tratamento de Reestenose Intra-Stent  
em Óstio da Artéria Descendente Anterior
A intervenção coronariana percutânea com balão farmacológico 
surgiu como estratégia adjunta no cenário da Cardiologia Inter-
vencionista. Em comparação com o stent farmacológico, o balão 
farmacológico oferece vantagens, como a liberação imediata 
e homogênea do fármaco na parede arterial, a ausência de 
polímeros que podem induzir a reações inflamatórias crônicas 
e o potencial de utilizar a dupla anti-agregação plaquetária 
por menor tempo. Além disso, em algumas situações, não 
são desejáveis implantes adicionais de stents, o que torna 
essa modalidade uma opção interessante. Relatamos aqui o 
caso de uma paciente em síndrome coronariana aguda, em 
que foi feita a opção por esse tipo de intervenção em uma 
reestenose de stent não farmacológico em óstio de artéria 
descendente anterior.
DESCRITORES: Reestenose coronária. Intervenção coronária 
percutânea. Angioplastia com balão. Paclitaxel.
Case Report
T he drug-eluting balloon has been standing out as a promising feature in the therapeutic armamen-tarium of interventional cardiology.1 It is known 
that prolonged release medication is essential for inhib-
iting neointimal proliferation promoted by drug-eluting 
stents.2 However, about 85% of the vessel area which 
receives the stent is not covered by the device’s stems, 
resulting in lower concentrations of antiproliferative drug 
in these regions.3 Compared to drug-eluting stents, the 
drug-eluting balloon offers advantages, such as an im-
mediate and homogeneous release of the drug in the 
arterial wall, the absence of polymers that can induce 
chronic inflammatory reactions, and the potential for 
use of dual antiplatelet therapy for a shorter time.4
The idea that drug-eluting balloons have certain 
indications where stenting procedures are not desirable 
is quite reasonable; for example, when an in-stent re-
stenosis occurs, in cases of small caliber vessels, diffuse 
injuries, or bifurcations.5 Another growing indication for 
the drug-eluting balloon is its use in peripheral vessels, 
with promising results.6
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study, demonstrating maintenance of the angiographic 
result obtained by the procedure (Figures 3A and B).
DISCUSSION
In this report, the use of a drug-eluting balloon 
was an effective alternative for the treatment of in-stent 
restenosis in a left anterior descending artery ostium. 
Preclinical8,9 and randomized1,9,10 studies consistently 
demonstrate that paclitaxel, in a matrix of soluble 
additives attached to the balloon, reduces neointimal 
formation, late lumen loss, restenosis, and target vessel 
revascularization in patients with restenotic lesions.
In the first-in-man randomized study, Treatment of 
In-Stent Restenosis by Paclitaxel Coated PTCA Balloons 
(PACCOCATH ISR), Scheller et al.1 evaluated the use of 
a paclitaxel-eluting balloon (Orbus X, Bavaria Medizin 
Technologie GmbH –Oberpfaffenhofen, Germany) in 
comparison to a conventional balloon for the treatment 
of in-stent restenosis. The patients received preprocedural 
acetylsalicylic acid (ASA) and clopidogrel (loading dose 
of 300 to 600 mg, maintenance dose of 75 mg/day), 
with maintenance for one month, followed by ASA 100 
mg indefinitely. At 6 months, the angiography showed 
that the late lumen loss measured 0.03 ± 0.48 mm vs. 
0.74 ± 0.86 mm (p = 0.002) and that the binary reste-
nosis rate was 5% vs. 43% (p = 0.002), respectively. 
At 12 months, the rate of major adverse cardiac events 
was 4% vs. 31% (p = 0.01), a difference that occurred 
mainly due to the reduced need for revascularization 
of the target lesion.
CASE REPORT
A female patient, 39 years old, hypertensive and a 
smoker, was admitted with a diagnosis of medium-risk 
unstable angina. The coronary angiography revealed a 
severe lesion in the ostium of the left anterior descend-
ing artery, treated with a bare-metal stent (3.0 × 12 
mm), with immediate satisfactory angiographic result 
(Figures 1A and B). Asymptomatic after five months, the 
patient was readmitted with high-risk unstable angina. 
A new coronary angiography showed diffuse in-stent 
restenosis (Figures 2A and B). 
The myocardial revascularization surgery indication 
was considered because the patient had low surgical 
risk (EuroSCORE II: 1.23%), 7 by the complexity of the 
procedure due to the possibility of stent placement in 
the distal left main coronary trunk, and because it was 
a recurrent lesion. The joint decision of this cardiol-
ogy team (clinical, interventional, and surgical) was in 
favor of a percutaneous coronary intervention with a 
paclitaxel-eluting balloon. The procedure consisted of 
predilation with a 3.0 × 20 mm Mytra® semi-compliant 
balloon (Scitech, Goiânia, Brazil) at 16 atm, followed by 
a 3.5 × 25 mm Pantera Lux® paclitaxel-eluting balloon 
(Biotronik, Bulach, Switzerland) at 14 atm, maintaining 
the insufflation for 90 seconds (Figures 2C and D).
During the in-hospital evolution, the patient suf-
fered a procedure-related infarct (type 4a), with no 
other complications, and was discharged to outpatient 
follow-up. After seven months, the patient returned to 
the service in an asymptomatic state for a scheduled 
Figure 1 – Percutaneous coronary intervention index. (A) Injury in the ostium of the left anterior descending artery. (B) Result after bare-stent implantation.
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Subsequently, in the study Paclitaxel-Eluting PTCA-
Balloon Catheter in Coronary Artery Disease II (PEPCAD 
II), Unverdorben et al.11 compared a second-generation 
paclitaxel-coated balloon (B. Braun Melsungen AG, 
Vascular Systems, Berlin, Germany) versus the Taxus® 
Liberté® paclitaxel-eluting stent in the treatment of 
bare-metal stent restenosis. The patients received pre-
procedural ASA and clopidogrel (loading dose of 300 to 
600 mg, maintenance of 75 mg/day), with maintenance 
for three months in the balloon-treated group and for 
6 months in the stent-treated group, followed by ASA 
100 mg indefinitely. After 6 months, the late luminal 
loss in the segment was 0.17 ± 0.42 mm vs. 0.38 ± 
0.61 mm (p = 0.03), resulting in a binary restenosis 
rate of 7% and 20%, respectively (p = 0.06). After 12 
months, the rate of major adverse cardiac events was 
Figure 2 – Treatment of in-stent restenosis. (A and B) Diffuse in-stent restenosis in the ostium and proximal portion of the left anterior descending 
artery. (C and D) Intervention with drug-eluting balloon.
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9% vs. 22% (p = 0.08), and the difference occurred 
primarily due to a reduced need for repeat coronary 
artery bypass graft (CABG) (6% vs. 15%; p = 0.15).11
Based on the results of PACCOCATH ISR and 
PEPCAD II studies, guidelines for CABG from the 
European Society of Cardiology/European Association 
for Cardio-Thoracic Surgery have provided a Class 2A 
recommendation (level of evidence B) for this modality 
in the treatment of bare-metal stent restenosis.12
Recently, in the randomized study RIBS V (Restenosis 
Intra-stent of Bare Metal Stents: Paclitaxel-eluting Balloon 
vs. Everolimus-eluting Stent.), Alfonso et al.13 compared 
the SeQuent® Please paclitaxel-eluting balloon (B. Braun 
Surgical, Melsungen, Germany) versus the Xience Prime® 
everolimus-eluting stent (Abbott Vascular, Abbott Park, 
United States) for treating in-stent restenosis. A total 
of 189 patients with bare-metal stent restenosis were 
included. All patients were pre-treated with ASA and 
clopidogrel. Clopidogrel (75 mg/day) was recommended 
for the months after the drug-eluting balloon and for 12 
months after the stent; and ASA was maintained indefi-
nitely. In a late angiography, those patients in the group 
treated with the stent had a smaller lumen diameter 
in the segment (2.01 mm ± 0.6 vs. 2.36  ±  0.6 mm; 
p < 0.001) and a significantly higher stenosis diameter 
in the segment (25 ± 20% vs. 13 ± 17%; p  <  0.001). 
However, the late lumen loss (0.14 ± 0.5 vs. 0.04 ± 
0.5 mm; P = 0.14) and the binary restenosis rate (9.5% 
vs. 4.7%; P = 0.22) in the segment were low, and were 
similar in both groups. The occurrence of combined 
clinical events (cardiac death, myocardial infarction, 
and target-vessel CABG) after 1 year was 6% vs. 8% 
(p = 0.60), and the need for target-vessel CABG was 
2% vs. 6% (p = 0.17), respectively.
The value of a drug-eluting balloon in patients with 
drug-eluting stent restenosis was also established.14,16 A 
randomized multicenter study confirmed the superiority 
of thedrug-eluting balloon versus angioplasty with use 
of a conventional balloon.14 The randomized multicenter 
study Intra-coronary Stenting and Angiographic Results: 
Drug Eluting Stents for In-Stent Restenosis 3 (ISAR-DESIRE 
3)15 investigated the efficacy of a drug-eluting balloon, 
a paclitaxel-eluting stent, and a conventional balloon 
in patients with drug-eluting stent restenosis. The study 
demonstrated not only the non-inferiority of the drug-
eluting balloon as compared with the paclitaxel-eluting 
stent, but also the superiority of these two strategies 
compared to conventional balloon angioplasty. Addi-
tionally, a recent randomized study suggested that the 
drug-eluting balloon is more effective in patients with 
bare-metal stent restenosis than in those with drug-
eluting stent restenosis.16
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Figure 3 – Angiographic control seven months post-intervention.
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